Biomarker development in MET-targeted therapy

Yanni Zhang; Zhiqiang Du; Mingqiang Zhang

doi:10.18632/oncotarget.8276

journal article Mar 22, 2016

Biomarker development in MET-targeted therapy

Yanni Zhang

Zhiqiang Du Mingqiang Zhang

Oncotarget Vol. 7 No. 24 pp. 37370-37389 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.8276

Topics

No keywords indexed for this article. Browse by subject →

References

116

[1]

Comoglio "MET signalling: principles and functions in development, organ regeneration and cancer" Nat Rev Mol Cell Biol (2010) 10.1038/nrm3012

[2]

Vande Woude "Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases" Proc Natl Acad Sci U S A (1988) 10.1073/pnas.85.1.21

[3]

Kitamura "Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor" Nature (1995) 10.1038/373702a0

[4]

Birchmeier "Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development" J Cell Biol (1993) 10.1083/jcb.123.1.223

[5]

Trusolino "Drug development of MET inhibitors: targeting oncogene addiction and expedience" Nat Rev Drug Discov (2008) 10.1038/nrd2530

[6]

Park "Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase" Oncogene (1994)

[7]

Comoglio "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family" Cell (1994) 10.1016/0092-8674(94)90318-2

[8]

Vande Woude "Met receptor tyrosine kinase: enhanced signaling through adapter proteins" Oncogene (2000) 10.1038/sj.onc.1203859

[9]

Giordano "Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages" J Exp Med (2008) 10.1084/jem.20072602

[10]

Giordano "Sema4D induces angiogenesis through Met recruitment by Plexin B1" Blood (2005) 10.1182/blood-2004-07-2885

[11]

Tsao "Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line" Neoplasia (2000) 10.1038/sj.neo.7900080

[12]

Comoglio "Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger" J Biol Chem (1993) 10.1016/s0021-9258(18)98327-4

[13]

Park "Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program" Mol Biol Cell (2003) 10.1091/mbc.e02-06-0352

[14]

Testa "Anti-apoptotic signaling by hepatocyte growth factor/Metthe phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways" Proc Natl Acad Sci U S A (2001) 10.1073/pnas.98.1.247

[15]

Tsao "An overview of the c-MET signaling pathway" Ther Adv Med Oncol (2011) 10.1177/1758834011422556

[16]

Clifford "HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop" BMC Cancer (2011) 10.1186/1471-2407-11-180

[17]

Park "Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases" Cancer Cell (2003) 10.1016/s1535-6108(03)00136-3

[18]

Ponta "Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin" Mol Biol Cell (2007) 10.1091/mbc.e06-08-0674

[19]

Salgia "Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer" J Carcinog (2008) 10.4103/1477-3163.44372

[20]

Comoglio "Cross-talk between the proto-oncogenes Met and Ron" Oncogene (2000) 10.1038/sj.onc.1203620

[21]

Chow "Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer" BMC Cancer (2011) 10.1186/1471-2407-11-139

[22]

Met, metastasis, motility and more

Carmen Birchmeier, Walter Birchmeier, Ermanno Gherardi et al.

Nature Reviews Molecular Cell Biology 2003 10.1038/nrm1261

[23]

Salgia "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition" Cytokine Growth Factor Rev (2002) 10.1016/s1359-6101(01)00029-6

[24]

Haber "Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752" Proc Natl Acad Sci U S A (2006) 10.1073/pnas.0508776103

[25]

Zarnegar "Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines" Hepatology (1997) 10.1002/hep.510260108

[26]

Zbar "Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype" Am J Pathol (1999) 10.1016/s0002-9440(10)65147-4

[27]

Jang "Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas" Cancer Res (1999)

[28]

Schwall "Somatic mutations lead to an oncogenic deletion of met in lung cancer" Cancer Res (2006) 10.1158/0008-5472.can-05-2749

[29]

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Alex Kentsis, Casie Reed, Kim L Rice et al.

Nature Medicine 2012 10.1038/nm.2819

[30]

Comoglio "Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene" Cancer Cell (2003) 10.1016/s1535-6108(03)00085-0

[31]

Comoglio "Ets up-regulates MET transcription" Oncogene (1996)

[32]

Pals "Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer" Cancer Res (2002)

[33]

Giordano "MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer" Clin Cancer Res (2012) 10.1158/1078-0432.ccr-11-1699

[34]

Hong "Progress in cancer therapy targeting c-Met signaling pathway" Arch Pharm Res (2012) 10.1007/s12272-012-0402-6

[35]

Vande Woude "Targeting MET in cancer: rationale and progress" Nat Rev Cancer (2012) 10.1038/nrc3205

[36]

Yamamoto "Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features" Oncology (1998) 10.1159/000011898

[37]

Jang "Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target" Oncol Rep (2011)

[38]

Clark "MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib" J Clin Oncol (2011) 10.1200/jco.2011.35.4928

[39]

Li "MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy" Cancer (2014) 10.1002/cncr.28454

[40]

Kim "MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome" Br J Cancer (2012) 10.1038/bjc.2012.237

[41]

Qian "HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma" Br J Cancer (2014) 10.1038/bjc.2014.61

[42]

Park "Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma" Hepatology (2013) 10.1002/hep.26402

[43]

Okusaka "Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma" Int J Clin Oncol (2013) 10.1007/s10147-011-0361-9

[44]

Cui "Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer" J Biomed Res (2013) 10.7555/jbr.27.20130004

[45]

Chung "High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer" J Thorac Oncol (2010) 10.1097/jto.0b013e3181ce3d1d

[46]

Yu "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib" Proc Natl Acad Sci U S A (2007) 10.1073/pnas.0710370104

[47]

Akhavanfard "Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC" Cancer Cell (2010) 10.1016/j.ccr.2009.11.022

[48]

Rogers "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling" Science (2007) 10.1126/science.1141478

[49]

Vande Woude "A novel germ line juxtamembrane Met mutation in human gastric cancer" Oncogene (2000) 10.1038/sj.onc.1203874

[50]

Lee "The transcriptional landscape and mutational profile of lung adenocarcinoma" Genome Res (2012) 10.1101/gr.145144.112

Showing 50 of 116 references

Metrics

38

Citations

116

References

Details

Published: Mar 22, 2016
Vol/Issue: 7(24)
Pages: 37370-37389

Authors

Y

Yanni Zhang

Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd, Shanghai, China

Z

Zhiqiang Du

Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd, Shanghai, China

M

Mingqiang Zhang

Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd, Shanghai, China

Cite This Article

Yanni Zhang, Zhiqiang Du, Mingqiang Zhang (2016). Biomarker development in MET-targeted therapy. Oncotarget, 7(24), 37370-37389. https://doi.org/10.18632/oncotarget.8276

Biomarker development in MET-targeted therapy

You May Also Like